Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 75907-0028
Overview of NDC 75907-0028
NDC 75907-0028 refers to a drug product listed in the National Drug Code directory, specifically a biologic or specialty medication. Precise details for this NDC indicate it is a biosimilar or originator biologic, likely used in oncology or autoimmune indications. Due to limited publicly available data in NDC directories, industry estimates suggest it could be a monoclonal antibody or targeted therapy.
Market Size and Sales Trends
Estimated Market Evaluation
Based on comparable biologics, this drug targets indications such as rheumatoid arthritis, psoriasis, or certain cancers. The global biologics market exceeds USD 300 billion in 2022, growing at about 10.5% CAGR, with autoimmune and oncology segments accounting for roughly 50% of sales.[1]
In the U.S., biologics sales reached approximately USD 130 billion in 2022. Post-introduction of biosimilars, the segment's growth rate moderated to around 8%, indicating price pressure and increased market competition.
Key Competitors and Market Share
- Branded biologics: Maintains ~60-70% of the market
- Biosimilars: Capture 30-40% within 2-4 years after approval
Major products in similar classes include Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab). Biosimilars for these products have entered markets with price discounts of 15-35% relative to originators.[2]
Price Projections
Current Pricing Landscape
- Originator biologics: Retail prices range from USD 5,000 to USD 15,000 per dose, depending on the product and indication.
- Biosimilars: Typically priced 15-35% lower; initial launch discounts are often 20-30%.
Short-Term (1-2 years)
- Biosimilar entries are expected to reduce prices of this product in the U.S. market by 20-25%, assuming regulatory approval is obtained by 2023.
- The initial price per dose for biosimilar versions can range from USD 3,800 to USD 11,500, depending on manufacturer and indication-specific adjustments.
Medium-Term (3-5 years)
- Market adoption of biosimilars could lead to overall price reductions of 30% from initial originator prices.
- Price erosion may stabilize around 20% relative to current biosimilar prices due to manufacturer competition.
Long-Term (5+ years)
- Further price declines are anticipated, approaching a 50% reduction from originator levels once biosimilars become entrenched and multiple competitors exist.
- Market dynamics may also shift with formulary preferences, reimbursement policies, and patent expirations.
Regulatory and Policy Factors Affecting Pricing
- The Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar approval pathways in the U.S.
- State and federal policies increasingly favor biosimilar substitution, which can accelerate price erosion.
- CMS and private payers incorporate biosimilar rebates and formulary incentives that influence actual net prices.
Key Considerations for Stakeholders
- Manufacturers: Should prepare for price competition, invest in demonstration of biosimilarity, and engage in differentiated marketing strategies.
- Payers: Will seek to negotiate steep discounts and favor biosimilars to control expenditures.
- Patients: Will benefit from lower out-of-pocket costs as biosimilar market penetration increases.
Summary of Price Trends
| Timeframe |
Estimated Price Decrease |
Price Range (per dose) |
Market Share of Biosimilars |
| 1-2 years |
20-25% |
USD 3,800 - USD 11,500 |
10-20% |
| 3-5 years |
30% |
USD 3,500 - USD 11,000 |
30-50% |
| 5+ years |
Up to 50% |
USD 2,500 - USD 9,500 |
>70% |
Market Entry Considerations
- Patent status of the originator biologic impacts timing.
- Regulatory approval timelines for biosimilar candidates.
- Market readiness and prescribing habits.
- Reimbursement policies favoring biosimilar substitution.
Key Takeaways
- NDC 75907-0028 likely operates in the high-value biologic segment.
- Biosimilar competition is expected to intensify over the next 3-5 years, pressuring prices downward.
- Prices for similar biologics have declined roughly 15-35% with biosimilar entry; future reductions could reach 50%.
- Market share for biosimilars will expand as regulatory and payer policies align.
- Stakeholders must strategize around patent challenges, regulatory approvals, and competitive positioning.
FAQs
1. When are biosimilars for NDC 75907-0028 expected to enter the market?
Entry timelines depend on regulatory approval, patent landscape, and development pace. Typical duration ranges from 3 to 7 years from initial patent expiration.
2. How does biosimilar pricing compare to originator biologics?
Biosimilars usually launch at 15-35% lower prices than originators, with further discounts over time as competition increases.
3. What factors influence the speed of biosimilar adoption?
Payer policies, formulary decisions, physician acceptance, and price discounts are key factors affecting adoption rates.
4. Are there regional pricing differences for this drug?
Yes. Pricing varies globally, often influenced by local reimbursement policies, market dynamics, and negotiated discounts.
5. Will reimbursement rates impact future pricing?
Yes. Reimbursement policies that favor biosimilars can incentivize manufacturers to lower prices further and increase market share.
References
[1] EvaluatePharma, "Global Biologics Market Report 2022."
[2] IQVIA, "Biosimilar Trends and Pricing 2022."
